WO2024255913A1 - Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation - Google Patents

Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2024255913A1
WO2024255913A1 PCT/CN2024/099748 CN2024099748W WO2024255913A1 WO 2024255913 A1 WO2024255913 A1 WO 2024255913A1 CN 2024099748 W CN2024099748 W CN 2024099748W WO 2024255913 A1 WO2024255913 A1 WO 2024255913A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
herpes virus
targeted
plaster
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/099748
Other languages
English (en)
Chinese (zh)
Inventor
张振涛
张佳奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CN2024/099748 priority Critical patent/WO2024255913A1/fr
Publication of WO2024255913A1 publication Critical patent/WO2024255913A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/758—Zanthoxylum, e.g. pricklyash
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the first application was filed by the State Intellectual Property Office of China on December 18, 2020, with application number 202011499992.9, and the name is: Targeted inactivation of herpes virus plaster drug preparation method and application;
  • the second application number is 202110416934.3, the application date is April 19, 2021, and the name is: Targeted inactivation of herpes virus plaster drug preparation method and application;
  • the third application number is PCT/CN2021/000191, the application date is September 18, 2021, and the name is: Targeted inactivation of herpes virus plaster drug preparation method and application; PCT/CN2022/000056, the application date is March 29, 2022, and the name is: Targeted inactivation of herpes virus plaster drug preparation method and application;
  • the invention relates to the technical field of pharmaceutical preparations, comprising a nitrate, preferably selected from sodium nitrate and potassium nitrate, the upstream and downstream of sodium nitrate and potassium nitrate and their derivatives, and chemical elements of active ingredients thereof, and specifically relates to a targeted herpes virus treatment plaster composition for treating herpes virus, a preparation method thereof, and use of the plaster composition in preparing a targeted herpes virus treatment drug.
  • Herpes viruses are a group of enveloped DNA viruses with similar biological characteristics, and are classified as herpes viruses. A total of more than 100 species have been discovered, which can be divided into three major categories (subfamilies) of a, b, and y, as well as other herpes viruses. They infect a wide range of hosts, mainly attacking the skin, mucous membranes, and nervous tissues, seriously affecting the health of humans and other animals. Quoting Baidu Encyclopedia. Viruses are small, simple in structure, A non-cellular organism that contains only one type of nucleic acid (RNA or DNA) and must parasitize and replicate inside a living cell. Quoted from Baidu Encyclopedia.
  • the herpes virus is one or more selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus type 6, human herpes virus type 7, human herpes virus type 8, AIDS, genital herpes, oral herpes, and herpes virus.
  • Targeted inactivation refers to the actual therapeutic effect.
  • Nitrates Sodium nitrate and potassium nitrate and their upstream and downstream and derivatives are preferred. They have been invented for hundreds of years. After various experiments, no drug has been invented to treat viruses, tumors, cancer, AIDS, bacteria, fungi, microorganisms, inflammation, and herpes. Nitrate compounds directly act on the lesion site, or various medical carriers deliver drugs to act on the lesion site, or various medical carriers deliver drugs directly into the lesion site, or various medical carriers deliver drugs to accumulate or release active ingredients in the target site, or various medical carriers deliver drugs to accumulate or release active ingredients in the target site, which can treat a variety of diseases.
  • Nitrate compounds can significantly increase the therapeutic effect by using the following technical solutions, such as nitroglycerin, which can treat heart disease.
  • the targeted drug of the present invention has the efficacy of treating herpes virus in the human body. After multiple human trials, it was found that the drug can effectively treat herpes virus without serious side effects.
  • the targeted treatment of herpes virus plaster composition of the invention comprises the following ingredients: plaster, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, mint, sodium saccharin, naringin, campanula extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethylcellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, appropriate amount of purified water, strontium chloride hexahydrate, tranexamic acid, Zanthoxylum bungeanum extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, herpes virus infection, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • the friction agent is one or more of calcium carbonate, calcium hydrogen phosphate, hydrated silica, calcium pyrophosphate, and aluminum hydroxide, preferably calcium carbonate and hydrated silica, with a weight percentage of 1% to 50%;
  • the surfactant is one or more of sodium lauryl sulfate, lauroyl sarcosine, and polysorbate derivatives, preferably sodium lauryl sulfate, the weight percentage of which is 0.1% to 3%;
  • the preservative is one or more of parabens and sodium benzoate, preferably sodium benzoate, the weight percentage of which is 0.05% to 0.2%;
  • Mint the weight percentage is 0.5% to 1.5%
  • the sweetener is saccharin sodium, and its weight percentage is 0.1% to 1%;
  • Thickener is one or more of hydroxyethyl cellulose, xanthan gum, trisodium phosphate, cellulose gum Species, the weight percentage is 0.05% to 4%;
  • the moisturizing agent is one or more of sorbitol, xylitol, and polyethylene glycol-8, preferably sorbitol and polyethylene glycol-8, with a weight percentage of 2% to 21%;
  • the binder is hydroxypropyl guar gum, and its weight percentage is 0.05% to 1%;
  • Patches plasters, patches, ointments, thin patches that can be cut according to the size of the affected area, and various thin patches.
  • the pharmaceutical composition of the present invention comprises the following ingredients: patch, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, mint, sodium saccharin, naringin, campanula extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethylcellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, appropriate amount of purified water, strontium chloride hexahydrate, tranexamic acid, Zanthoxylum bungeanum extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, herpes virus infection, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, in order to give the patient the best therapeutic effect, the dosage regimen of the ingredients in the present invention can be widely varied.
  • Example 1 Patch, malic acid 1%, sorbitol 20%, calcium carbonate 36%, hydroxyethyl cellulose 1%, sodium benzoate 0.2%, cellulose gum 0.5%, hydroxypropyl guar gum 1%, mint 1%, saccharin sodium 0.46%, sodium nitrate 2%, hydrated silica 10%, sodium lauryl sulfate 2.8%, purified water, strontium chloride hexahydrate 0.8%, tranexamic acid 0.5%.
  • This example is a test example included in the present invention.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 2 Patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, saccharin sodium 0.36%, sodium nitrate 1%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water, strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%.
  • This example is a test example included in the present invention.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 3 patch, malic acid 1.5%, sorbitol 21%, calcium carbonate 45%, hydroxyethyl cellulose 0.7%, sodium benzoate 0.18%, cellulose gum 0.7%, hydroxypropyl guar gum 0.7%, mint 0.7%, saccharin sodium 0.35%, sodium nitrate 0.4%, hydrated silica 5%, sodium lauryl sulfate 2.7%, purified water, strontium chloride hexahydrate 0.75%, tranexamic acid 0.6%.
  • This example is a test example of the present invention.
  • the dosage regimen of the components implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, disease
  • the dosage regimen of the components of the invention may vary widely, depending on the severity of the condition, the route of administration, and the activity of the particular compound used. Therefore, the dosage regimen of the components of the invention may vary widely to provide the patient with the optimal therapeutic effect.
  • Compound 1 malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, cellulose gum + hydroxyethyl cellulose 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, hydroxypropyl guar gum 0.05%-1%, sodium nitrate 0.05%-2%, sodium lauryl sulfate 0.1%-3%, strontium chloride hexahydrate 0.1%-2.5%, tranexamic acid 0.1%-2% and the balance of purified water;
  • the above composition and patch are made into a plaster.
  • the above composition is made into toothpaste.
  • Compound 2 0.05% to 2% sodium nitrate, 0.1% to 2.5% strontium chloride hexahydrate and the balance of purified water;
  • the above composition and patch are made into a plaster.
  • Compound 3 0.05% to 2% sodium nitrate and the balance of purified water;
  • the above composition and patch are made into a plaster.
  • Compound 4 sodium nitrate 0.05% to 2%;
  • the above composition and patch are made into a plaster
  • Example 4 Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, saccharin sodium 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water, 2% of Zanthoxylum bungeanum extract, 0.6% of naringin, 1.5% of Campanula officinalis extract, 0.6% of xanthan gum, 2% of (polyethylene glycol-8).
  • This example is a test example included in the present invention.
  • the dosage regimen of the components implemented by the pharmaceutical composition of the present invention is based on various factors.
  • the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 5 Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, saccharin sodium 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water, 2%, Zanthoxylum bungeanum extract 2%, naringin 0.6%, Campanula extract 1.5%, xanthan gum 0.6%, (polyethylene glycol-8) 2%.
  • This example is a test example included in the present invention.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection, age, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 6 Patch, malic acid 1.5%, sorbitol 18%, sodium benzoate 0.15%, cellulose gum 1%, mint 0.9%, saccharin sodium 0.35%, trisodium phosphate 0.4%, hydrated silica 36%, sodium lauryl sulfate 2.8%, purified water, 2%, Zanthoxylum bungeanum extract 2%, naringin 0.6%, Campanula extract 1.5%, xanthan gum 0.6%, (polyethylene glycol-8) 2%.
  • This example is a test example included in the present invention.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, herpes virus infection, age, weight, sex and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Compound 5 malic acid 0.08%-2.5%, polyethylene glycol-8 + sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum + xanthan gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, naringin 0.002%-2%, campanula extract 0.01%-3%, hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, two-sided needle extract 0.1%-4.3% and the balance of purified water
  • the above composition and patch are made into a plaster.
  • the above composition is made into toothpaste.
  • Compound 6 0.002% to 2% naringin, 0.01% to 3% of Campanula extract, 0.1% to 4.3% of Zanthoxylum bungeana extract and the balance of purified water; if purified water is not needed, no water is added;
  • Preparation method naringin, Campanula extract, Zanthoxylum bunge extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin, Campanula extract, Zanthoxylum bunge extract are mixed according to the conventional formula amount.
  • the above composition and patch are made into a plaster.
  • Compound 7 0.002% to 2% naringin, 0.1% to 4.3% Zanthoxylum bunge extract and the balance of purified water; if purified water is not needed, no water is added;
  • Preparation method naringin, dianthus chinensis extract and the remaining amount of purified water are mixed according to the conventional formula amount; naringin and dianthus chinensis extract are mixed according to the conventional formula amount.
  • the above composition and patch are made into a plaster.
  • Example 7 Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water, sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 1%, phosphoric acid Trisodium 0.36%, sodium chloride 0.5%.
  • This example is a test example of the present invention, and the dosage regimen of the components implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the components in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 8 Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water, sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 1.6%, trisodium phosphate 0.36%, sodium chloride 0.5%.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Example 9 Patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 38%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, saccharin sodium 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water, sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.36%, sodium chloride 0.5%.
  • the dosage regimen of the ingredients implemented by the pharmaceutical composition of the present invention is based on a variety of factors, including patient type, age, weight, herpes virus infection, gender and medical condition, severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the ingredients in the present invention can be widely varied to give the patient the best therapeutic effect.
  • Preparation method prepare a mixing container and a tube-shaped product for the paste
  • Compound 8 malic acid 0.08%-2.5%, sorbitol 2%-21%, sodium benzoate 0.05%-0.2%, trisodium phosphate + cellulose gum 0.05%-4%, mint 0.5%-1.5%, saccharin sodium 0.1%-1%, calcium carbonate + hydrated silica 1%-50%, sodium lauryl sulfate 0.1%-3%, sodium monofluorophosphate 0.001%-1%, sea salt 0.01%-0.9%, potassium nitrate 0.05%-2%, sodium chloride 0.01%-0.9% and the balance of purified water;
  • the above composition and patch are made into a plaster.
  • the above composition is made into toothpaste.
  • Compound 9 0.001% to 1% sodium monofluorophosphate, 0.05% to 2% potassium nitrate, and an appropriate amount of purified water;
  • Preparation method Sodium monofluorophosphate, potassium nitrate and an appropriate amount of purified water are mixed according to the conventional formula amount; Sodium monofluorophosphate and potassium nitrate are mixed according to the conventional formula amount.
  • the above composition and patch are made into a plaster.
  • Preparation method Sodium nitrate and sodium monofluorophosphate are mixed according to the conventional formula.
  • the above composition and patch are made into a plaster.
  • Combination therapy Compound 1 and Compound 5;
  • Combination therapy Compound 10 and Compound 5;
  • Combination therapy Compound 10 and Compound 6;
  • Combination therapy Compound 1, Compound 6, Compound 10;
  • Combination therapy Compound 1, Compound 10;
  • the above compound drugs can be used alone.
  • the combination of the three compound drugs mentioned above is more effective than using them alone or using two drugs in combination one after the other, and can treat recurrent and drug-resistant diseases.
  • Some recurrent and drug-resistant diseases can be completely cured without recurrence.
  • targeted drug delivery system or targeted delivery system lesion site drug delivery system or lesion site delivery system, injection, interventional therapy, targeted drugs, infection site drug delivery, drug carrier delivery of drugs to and/or into target sites, targeted therapy, intratumoral injection, Chemotherapeutic agents, targeted agents, or transdermal administration.
  • the pharmaceutical composition can be prepared into medicines in the form of aqueous solutions, injections, mixtures, lotions, liniments, aerosols, sprays, powders, pills, tablets, films, gels, capsules, ointments, suppositories, pastes, integrated ointments and patches, patches, and the like.
  • Experimental compound 1 patch, malic acid 1.3%, sorbitol 21%, calcium carbonate 36%, sodium benzoate 0.16%, cellulose gum 0.7%, mint 0.8%, sodium saccharin 0.36%, hydrated silica 12%, sodium lauryl sulfate 2.9%, purified water (particularly water), sodium monofluorophosphate 0.8%, sea salt 0.3%, potassium nitrate 2%, trisodium phosphate 0.36%, sodium chloride 0.5%.
  • Experimental compound 2 patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, saccharin sodium 0.36%, sodium nitrate 2%, hydrated silica 8%, sodium lauryl sulfate 3%, purified water (q. L), strontium chloride hexahydrate 0.65%, and tranexamic acid 0.5%.
  • Experimental compound 1 patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, saccharin sodium 0.36%, sodium nitrate 0.4%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water (q. L), strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%.
  • Patient Li Experimental compound: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, saccharin sodium 0.36%, sodium nitrate 1%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water, strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%. After one day of patching, genital herpes disappeared and inflammation also disappeared.
  • Patient Horse Experimental compound: patch, malic acid 1.8%, sorbitol 20%, calcium carbonate 40%, hydroxyethyl cellulose 1%, sodium benzoate 0.16%, cellulose gum 0.5%, hydroxypropyl guar gum 0.98%, mint 1%, saccharin sodium 0.36%, sodium nitrate 0.5%, hydrated silica 10%, sodium lauryl sulfate 3%, purified water, strontium chloride hexahydrate 0.65%, tranexamic acid 0.5%. After one day of patching, herpes simplex disappeared and inflammation also disappeared.
  • Some patients with severe conditions or serious diseases or recurring or drug-resistant conditions may require longer treatment times.
  • the active ingredient is sodium nitrate.
  • the active ingredients are potassium nitrate and sodium monofluorophosphate (containing fluoride). Or sodium nitrate, sodium monofluorophosphate (containing fluoride).
  • the active ingredients are Zanthoxylum bungeanum extract, naringin and Campanula officinalis extract; or the active ingredients are Zanthoxylum bungeanum extract and naringin.
  • the genital herpes disappeared the skin was a little red, and the inflammation also disappeared.
  • the herpes varicella decreased by three .
  • the fourth test genital herpes disappeared, the skin was a little red, the inflammation disappeared, and the herpes chickenpox disappeared...
  • the ingredients and dosages were different, which caused the results to be different from the first test. After many tests, in order to change the effect, other ingredients and dosages were used.
  • the herpes chickenpox disappeared, the inflammation also disappeared, and the duration of severe herpes would be prolonged. . . If the ointment is applied for a long time, it will cause slight dehydration of the skin.
  • herpes and chickenpox will now disappear. It takes a shorter time than existing drugs to treat herpes virus-related diseases and can effectively treat them without causing serious side effects.
  • a latent lesion of the size of a 2-cent coin appeared on the waist, which was different from the skin and uneven on the surface.
  • the herpes pox decreased. When the skin recovers, it is sometimes smooth. Slightly red. The skin is slightly dehydrated.
  • the first discovery of the efficacy of the drug in treating herpes was an accidental discovery, which can make herpes pox disappear in the body. After many human trials, because the drug has the efficacy of treating herpes virus in the human body.
  • the drug is administered transdermally according to the size of the disease site.
  • the plaster is applied and penetrates through the skin to the subcutaneous tissue at the site of infection, producing a relative advantage in drug concentration at the site of the disease, thereby exerting a stronger pharmacological effect.
  • the drug exerts a stronger pharmacological effect, treating a variety of herpes viruses ⁇ specifically and accurately inactivating latent herpes viruses in the body.
  • plaster pharmaceutical composition in the preparation of targeted herpes virus inactivation drugs: tumors, venereal diseases, hepatitis, pneumonia, COVID-19, AIDS, condyloma acuminatum, fungal diseases, lupus erythematosus , anthrax, palmotodigital pustulosis, cancer, herpes simplex virus, herpes virus, Epstein-Barr virus, virus, syphilis, tartar removal, diseases characterized by viruses, new coronary pneumonia, AIDS, genital warts, diseases characterized by herpes, viruses, bacteria, microorganisms, brain diseases, heart diseases, and inflammation.
  • the invention can be used to prepare various dosage forms of medicines such as patches, aqueous solutions, injections, mixtures, lotions, liniments, gel patches, aerosols, sprays, powders, pills, tablets, films, capsules, ointments, suppositories and pastes.
  • the component protection range of the targeted drug of the present invention is 0-100%.
  • compositions included in the present invention are compositions included in the present invention, and the dosage regimen of the components implemented by the pharmaceutical composition of the present invention is based on various factors, including patient type, age, weight, herpes virus infection situation, sex and medical condition, the severity of the condition, route of administration, and the activity of the specific compound used. Therefore, the dosage regimen of the components in the present invention can be widely changed to give the best therapeutic effect to the patient.
  • the present invention can be easily modified by medical workers. Any other changes, modifications, replacements, moves, mergers, improvements, changes, optimizations, combinations, simplifications, processing, refinements, imitations, and deepenings made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and shall be included in the protection scope of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de plâtre pour la thérapie ciblée du virus de l'herpès, laquelle composition contient les composants suivants : matrice de plâtre, phosphate trisodique, acide malique, sorbitol, benzoate de sodium, gomme de cellulose, menthe chinoise, saccharine sodique, naringine, un extrait de Clinopodium polycephalum, gomme xanthane, polyéthylène glycol-8, carbonate de calcium, hydroxyéthylcellulose, gomme de guar hydroxypropylée, nitrate de sodium, silice hydratée, laurylsulfate de sodium, chlorure de strontium hexahydraté, acide tranexamique, un extrait de Zanthoxyli radix, monofluorophosphate de sodium, sel de mer, nitrate de potassium, chlorure de sodium et une quantité appropriée d'eau purifiée.
PCT/CN2024/099748 2024-06-18 2024-06-18 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation Pending WO2024255913A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2024/099748 WO2024255913A1 (fr) 2024-06-18 2024-06-18 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2024/099748 WO2024255913A1 (fr) 2024-06-18 2024-06-18 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
WO2024255913A1 true WO2024255913A1 (fr) 2024-12-19

Family

ID=93851353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/099748 Pending WO2024255913A1 (fr) 2024-06-18 2024-06-18 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2024255913A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
CN101057953A (zh) * 2006-04-21 2007-10-24 陈祖辉 对付病毒感染疾患的多靶协同防治制剂
CN102525871A (zh) * 2012-03-13 2012-07-04 常熟华港制药有限公司 用于预防和治疗复发性口疮的牙膏及制备方法
CN108379139A (zh) * 2018-03-07 2018-08-10 济川药业集团有限公司 一种防治口腔溃疡的牙膏及其制备方法和应用
CN108938864A (zh) * 2018-06-19 2018-12-07 重庆太极实业（集团）股份有限公司 一种中药组合物在制备治疗疱疹病毒感染所致疾病的药物中的应用
WO2022206086A1 (fr) * 2021-04-19 2022-10-06 张振涛 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, procédé de préparation associé et utilisation associée

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
CN101057953A (zh) * 2006-04-21 2007-10-24 陈祖辉 对付病毒感染疾患的多靶协同防治制剂
CN102525871A (zh) * 2012-03-13 2012-07-04 常熟华港制药有限公司 用于预防和治疗复发性口疮的牙膏及制备方法
CN108379139A (zh) * 2018-03-07 2018-08-10 济川药业集团有限公司 一种防治口腔溃疡的牙膏及其制备方法和应用
CN108938864A (zh) * 2018-06-19 2018-12-07 重庆太极实业（集团）股份有限公司 一种中药组合物在制备治疗疱疹病毒感染所致疾病的药物中的应用
WO2022206086A1 (fr) * 2021-04-19 2022-10-06 张振涛 Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, procédé de préparation associé et utilisation associée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAO JING, ZHANG MEIYING , WANG YIFEI , WANG YAFENG , WANG XIAOYAN , PEI YING , YANG KE , QIAN TRAIWEN , ZHANG YINGJUN , YANG CHONG: "Experimental study on the anti-herpes simplex virus type 1 activity of 41 kinds of southern medicine extracts", ZHONGYAOCAI - JOURNAL OF CHINESE MEDICINAL MATERIALS, GUOJIA YIYAO GUANLIJU, CN, vol. 31, no. 8, 25 August 2008 (2008-08-25), CN , pages 1226 - 1229, XP055974159, ISSN: 1001-4454, DOI: 10.13863/j.issn1001-4454.2008.08.045 *

Similar Documents

Publication Publication Date Title
US10130648B2 (en) Therapeutic composition
JP6030130B2 (ja) 生薬等含有医薬組成物
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
CN104922130B (zh) 一种用于治疗带状疱疹的凝胶剂及其制备方法
TW304167B (fr)
US20030235627A1 (en) Topical administration of pharmacologically active bases in the treatment of warts
US20040258765A1 (en) Method for treatment of sores and lesions of the skin
CN104306447B (zh) 一种双藤微乳凝胶剂及其制备方法
AU781066B2 (en) Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof
WO2022206086A1 (fr) Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, procédé de préparation associé et utilisation associée
EP4248953A1 (fr) Pansement de gel de brucine, méthode de préparation et utilisation associées
KR20070054222A (ko) 진통 작용이 있는 약제 조성물
WO2024255913A1 (fr) Composition pharmaceutique de plâtre pour l'inactivation ciblée du virus de l'herpès, et son procédé de préparation et son utilisation
US20180133239A1 (en) Therapeutic composition
AU2024276277A1 (en) Pharmaceutical composition
EP2200585B1 (fr) Utilisation d'oxyde de deuterium pour traiter des affections cutanees d'origine virale
CN115737609A (zh) 一种含草乌甲素凝胶贴膏及其制备方法
JP4903057B2 (ja) いぼをテルル化合物により治療するための治療法および医薬組成物
CN101612203B (zh) 一种用于治疗尖锐湿疣的中药组合物及其应用
WO2019136196A1 (fr) Composition thérapeutique
CN111789832A (zh) 右酮洛芬氨丁三醇凝胶贴膏及其制备方法
RU2178693C2 (ru) Противовирусное средство для наружного применения на основе гиалуроновой кислоты
CN104940185A (zh) 刺芒柄花素的医药用途
US7618950B2 (en) Method for treatment and prevention of herpes zoster by topical application
WO2004069261A1 (fr) Procede de production d'une preparation contre le virus de l'herpes a usage externe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24822858

Country of ref document: EP

Kind code of ref document: A1